PR1 peptide

The PR1 peptide is a tumor-associated epitope specifically presented by HLA-A2 molecules on the surface of myeloid leukemia cells. It is derived from intracellular proteins proteinase 3 and neutrophil elastase, which are overexpressed in myeloid cancers. PR1 serves as the basis of a targeted peptide vaccine approach: vaccination with PR1 can induce expansion of PR1-specific CTLs, which mediate leukemia cell lysis and contribute to disease remission. Clinical trials have demonstrated immunogenicity and some objective responses in AML, CML, and MDS with minimal toxicity, establishing PR1 peptide as an investigational cancer immunotherapy target.

Other names

HLA-A2-restricted PR1 peptide

Induces expansion and activation of PR1-specific cytotoxic T lymphocytes (CTLs) that selectively lyse myeloid leukemia cells displaying the PR1 peptide on HLA-A2